Mismatch repair deficient rectal cancer: immunotherapy alone
The biopsy is stained for 4 repair proteins. Any one lost = deficient (dMMR). Many mutations, so PD-1 (programmed death 1) blockade works.
- Rectal exam: nothing felt
- Endoscopy: nothing seen
- Magnetic resonance imaging (MRI): no tumor
One dot, one patient: Cercek, N Engl J Med 2025
Rectum, stage II or III
None had the rectum removed. Recurrence-free at 2 years: 96%.
Other organs, stage I to III
33 chose no surgery.
Phase 2, three centers, one drug, no randomized comparison.
Stain before scalpel.
5 to 10% of rectal cancers are deficient. Deficient: germline testing for Lynch syndrome (inherited mismatch repair defect). Found in 8 of 14 rectal patients tested (Cercek, N Engl J Med 2022).
Sources
PubMed, checked Nov 20, 2026.
- Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022. First 12 consecutive patients: 12 of 12 clinical complete response. PubMed 35660797
- Cercek A, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025. Other organs: stomach and esophagus, colon, bile ducts and liver, genitourinary, gynecologic. PubMed 40293177
Anticoagulant pills around a procedure
Day 0: no dose on procedure day. Skip: no pill that day, both doses for apixaban and dabigatran. Restart: day 2 or 3, once bleeding is controlled. Half-life 8 to 14 hours: 1 day off is about 3 half-lives, 2 days about 5. Clearance below 30 (apixaban below 25): not studied in PAUSE, longer pause, ask pharmacy.
1 day low, 2 days high. Dabigatran with weak kidneys: double it.
Sources
PubMed, checked Nov 20, 2026.
- Douketis JD, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant (PAUSE). JAMA Intern Med 2019. Major bleeding at 30 days: apixaban 1.35%, dabigatran 0.90%, rivaroxaban 1.85%; after high-risk procedures, apixaban 2.96%, rivaroxaban 2.95%. Stroke or arterial embolism: 0.16%, 0.60%, 0.37%. PubMed 31380891
- Douketis JD, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE). N Engl J Med 2015. PubMed 26095867
- Douketis JD, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022. PubMed 35964704
- Patel IJ, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions, part II. J Vasc Interv Radiol 2019. PubMed 31229333